Baxter International Inc. Third Quarter 2011 Financial Results Conference Call

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its third quarter 2011 financial results on Thursday, October 20, 2011, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866-261-7280 (domestic) or 703-639-1228 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.

This call is being webcast by Thomson/CCBN and can be accessed at Baxter’s Web site at http://www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com. Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

Baxter International, Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



CONTACT:

Baxter International Inc.
Investor Relations Contact:
Mary Kay Ladone, +1-847-948-3371
[email protected]
or
Clare Trachtman, +1-847-948-3085
[email protected]

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical

MEDIA:

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.